Published in final edited form as:

J Mol Cell Cardiol. 2015 April ; 81: 46–48. doi:10.1016/j.yjmcc.2015.01.023.

Mitsugumin-53: Potential biomarker and therapeutic for myocardial ischemic injury?

Mark J. Kohr

Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205

Keywords

mitsugumin-53; tripartite motif-containing protein 72; cardioprotection; ischemic heart disease; ischemia-reperfusion injury

1. INTRODUCTION

Ischemia-reperfusion injury underlies many pathological conditions, including ischemic heart disease, which is a major cause of death worldwide [1]. Myocardial ischemia-reperfusion injury results from an interruption in the blood supply to a region of the heart, and is most often the result of acute coronary occlusion. Significant injury also occurs upon reperfusion of the ischemic region, as additional myocardial damage results from the formation of reactive oxygen species [2], which can trigger cell death by activating pro-apoptotic and/or necrotic signaling pathways in cardiomyocytes [3]. The issue of cell death is of paramount importance in the heart since cardiomyocytes are terminally differentiated, and aside from cardiac progenitor cells, the myocardium is very limited with regard to endogenous regenerative capabilities [4]. Cardioprotective interventions hold great promise for lessening the detrimental effects of myocardial ischemia-reperfusion injury [5], and have been shown to reduce contractile dysfunction, arrhythmogenesis and cell death in animal models [6–9]. In 1986, Murry and Reimer originally described the powerful cardioprotective phenomena known as ischemic preconditioning (IPC), whereby brief exposure to periods of ischemia and reperfusion serves to protect the heart against a more prolonged ischemic insult [6]. However, IPC must be performed prior to the onset of ischemia, thereby limiting clinical applicability. Since the initial discovery of IPC, additional protective mechanisms with greater clinical applicability have been described, including ischemic postconditioning [10], and pharmacologic agents such as adenosine [11], cyclosporine [12], and nitric oxide [13]. Mechanistically, there is much that remains to be defined, but these interventions are thought to converge on similar cytoprotective signaling pathways that may include the reperfusion injury salvage kinase (RISK) pathway, which is comprised primarily of phosphoinositide 3-kinase/Akt, ERK1/2, and glycogen synthase kinase 3 beta [14].

Corresponding Author: Mark J. Kohr, Ph.D., Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E7616, Baltimore, MD 21205, USA, Phone: 410-925-6156, Fax: 410-502-5862, mkohr1@jhu.edu.

DISCLOSURES

None.

Although research devoted to the elucidation of cardioprotective signaling pathways has been ongoing for nearly forty years, few experimental discoveries have translated successfully into effective therapeutics, and currently, the only established intervention that consistently reduces infarct size in humans is early coronary artery reperfusion, which still has the potential to cause additional myocardial injury as mentioned above. The recent study from Liu *et al.* brings a fresh perspective on potential therapeutic approaches for the treatment of ischemic heart disease with the use of recombinant protein, namely the membrane repair protein mitsugumin-53 [15].

2. ROLE OF MITSUGUMIN-53 IN CARDIOPROTECTION

Mitsugumin-53, also known as tripartite motif-containing protein 72, is a member of the large tripartite motif-containing family of proteins, and was recently characterized by Jianjie Ma's group as a critical membrane repair protein in heart and skeletal muscle [16, 17]. Membrane rupture is a main contributor to cardiomyocyte cell death following ischemia-reperfusion injury, and as such, membrane repair is an essential process for preserving cardiomyocyte viability [18]. Following membrane damage, the oxidizing milieu of the extracellular environment leads to the dimerization and activation of mitsugumin-53, which subsequently translocates to the site of injury [16, 17]. Mitsugumin-53 functions in membrane repair by recruiting essential repair components, including dysferlin, and serving as a scaffold to facilitate membrane repair [19]. Ischemia-reperfusion injury has been shown to decrease mitsugumin-53 levels in the heart, likely via oxidation-induced degradation [20], and this correlates directly with enhanced cellular injury [21]. In addition, the genetic ablation of mitsugumin-53 exacerbates myocardial ischemia-reperfusion injury, while mitsugumin-53 overexpression has been shown to be protective in cellular models of injury [21]. Mitsugumin-53 also plays an essential role in IPC and postconditioning, in part, by facilitating the activation of various components of the RISK signaling pathway [21, 22]. Interestingly, IPC has been shown to maintain mitsugumin-53 levels following ischemia-reperfusion injury, thereby reducing cell death. The maintenance of mitsugumin-53 levels occurs, in part, via IPC-induced S-nitrosylation, which stabilizes mitsugumin-53 by preventing oxidation-induced degradation [20]. Mitsugumin-53 also plays a role in cellular metabolism by functioning as an E3 ubiquitin ligase and targeting such proteins as the insulin receptor and insulin receptor substrate 1 [23].

The study from Liu *et al.* provides a comprehensive examination of recombinant mitsugumin-53 (rhMG53) as a potential therapeutic for myocardial ischemia-reperfusion injury using multiple animal models [15]. In a Langendorff-perfused mouse heart model of ischemia-reperfusion injury, the authors demonstrated an rhMG53-dependent reduction in creatine kinase release and infarct size when administered in the perfusate prior to ischemia or two minutes post-reperfusion. Similarly, using *in vivo* mouse and rat heart models of coronary artery occlusion, the authors demonstrated a dose-dependent reduction in creatine kinase release and infarct size upon the respective intraperitoneal (10 minutes post-reperfusion) or intravenous tail vein (two minutes post-reperfusion) administration of rhMG53. Recognizing the need to further validate the protective effects of rhMG53 in a large-animal model, the authors utilized a porcine model of angioplasty-induced myocardial infarction and observed that intravenous administration of rhMG-53 reduced infarct size,

decreased troponin I release, and decreased TUNEL positive staining as a marker of apoptosis after 24 hours of reperfusion. Similar protection was observed with rhMG53 regardless of whether it was administered prior to the onset of ischemia or at two minutes post-reperfusion. Interestingly, a similar degree of protection was also observed even when administration of rhMG53 was delayed until 30 minutes post-reperfusion. The authors also examined the sustained protective effects of rhMG53 administration in the porcine heart model by separately examining post-infarction remodeling. Hearts that were administered rhMG53 showed significantly enhanced fractional shortening and ejection fraction, as well as reduced fibrosis at four weeks post injury. Mechanistically, the recruitment of mitsugumin-53 to the site of injury has been well characterized [16, 17], but the mechanism underlying the recruitment of rhMG53 has not been fully examined. rhMG53 is thought to concentrate at the site of injury by binding phosphatidylserine [24], and the authors provide additional evidence in support of this hypothesis by demonstrating that rhMG53 preferentially targets infarcted tissue, as compared to adjacent or remote myocardium, and upregulates phospho-AKT and phospho-glycogen synthase kinase 3 beta. Regardless of the specific mechanism of action, rhMG53 does appear to provide substantial cardioprotective effects in the animal models that were examined. In addition to the use of mitsugumin-53 as a potential treatment for myocardial ischemia-reperfusion injury, Liu *et al.* also examined mitsugumin-53 as a potential biomarker for myocardial injury. Using an *in vivo* murine model, the authors demonstrated a low circulating level of mitsugumin-53 in the blood at baseline that increased dose-dependently with myocardial injury and this increase persisted for up to four hours. In addition, the authors showed that the increase in mitsugumin-53 levels in the perfusate with myocardial injury mirrors that of creatine kinase in the Langendorff-perfused mouse heart. These results are consistent with the findings of Marshall *et al.*, which also identified mitsugumin-53 as a potential marker for necrotic cellular injury [25].

3. CONCLUSIONS AND FUTURE PERSPECTIVES

Membrane repair is a vital process for maintaining cardiomyocyte viability following ischemia-reperfusion injury, and the study from Liu *et al.* provides compelling evidence in support of the use of rhMG53 as a potential therapeutic to combat the damaging effects of ischemia-reperfusion-induced membrane rupture [18]. The authors demonstrate powerful cardioprotective effects in mouse, rat and porcine models using rhMG53 [15], and since the porcine heart is anatomically similar to that of the human, these results provide strong support for the use of rhMG53 as a potential therapeutic for ischemic heart disease. In addition to protective effects observed in the myocardium, the authors have also demonstrated that rhMG53 administration can facilitate the repair of damaged skeletal muscle membranes, particularly in the setting of muscular dystrophy [24]. Additionally, rhMG53-dependent protection has also been observed in other cell types, including rat bone marrow-derived stem cells [26]. The fact that mitsugumin-53 can elicit protective effects in multiple cells types clearly broadens the therapeutic potential beyond that of myocardial injury. rhMG53 is also soluble in aqueous solutions and can be stored as a lyophilized powder at room temperature. The use of mitsugumin-53 as a potential biomarker for myocardial injury is also an intriguing possibility, but additional studies will have to be

conducted in order to establish the reliability of mitsugumin-53 as a biomarker compared to more commonly used markers, including troponin I, creatine kinase and lactate dehydrogenase.

Although the protective effects of rhMG53 have been characterized in the heart and skeletal muscle, mechanistic detail is lacking, and future studies will need to address key issues underlying the protective effects of rhMG53. For example, how does an intracellular protein provide protective effects when administered in the extracellular space? Intracellular mitsugumin-53 works to facilitate membrane repair by forming a dimer and translocating to sites of injury, but additional studies are necessary in order to establish whether rhMG53 also needs to dimerize in order to provide protective effects. Moreover, does rhMG53 need to gain entry into injured cells in order to provide protection? Since the authors demonstrated preferential targeting of damaged tissue by rhMG53, it is possible that rhMG53 facilitates protection by simply entering damaged cells through the site of membrane rupture. This is supported by the upregulation of protective intracellular signaling pathways (i.e., Akt, glycogen synthase kinase 3 beta). However, it is also possible that the mechanism underlying the protective effects of intracellular mitsugumin-53 is completely different from that of rhMG53. Furthermore, does the E3 ubiquitin ligase function play a role in the cytoprotective effects of mitsugumin-53? While membrane rupture is a major factor contributing to cardiomyocyte cell death following ischemia-reperfusion injury, one could envision that mitsugumin-53 may perhaps upregulate or downregulate essential cytoprotective pathways by altering the stability of target proteins. In addition, although enhanced mitsugumin-53 levels appear to be beneficial in the setting of myocardial ischemia-reperfusion injury, mitsugumin-53 upregulation can potentially trigger insulin resistance, obesity, and hypertension by degrading the insulin receptor and insulin receptor substrate 1 [23]. Therefore, it is of critical importance to also determine the half-life of rhMG53 in the bloodstream, and to examine the long term effects of acute rhMG53 administration on insulin signaling and cellular metabolism. Mutations and/or modifications to mitsugumin-53 may also serve to optimize the therapeutic benefit of rhMG53. For instance, the stability of rhMG53 itself may be improved, as we have recently demonstrated by developing a mutant variant of mitsugumin-53 that is resistant to oxidation-induced degradation [20]. In conclusion, rhMG53 appears to be a promising cytoprotective agent that has the potential to serve as a biomarker and as a therapeutic for the treatment of myocardial ischemic injury, and additional studies will aim to refine the use of rhMG53 in the heart and beyond.

Acknowledgments

This work was supported by NIH grant 1K99HL114721 (MK).

References

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. *Circulation*. 2012; 125:e2–e220. [PubMed: 22179539]
2. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. *Cardiovasc Res*. 2006; 70:181–90. [PubMed: 16580655]

3. Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32:1552–62.
4. Laflamme MA, Murry CE. Heart regeneration. Nature. 2011; 473:326–35. [PubMed: 21593865]
5. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, et al. New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation. 1172; 124(10):1172–9. [PubMed: 21900096]
6. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74(5):1124–36. [PubMed: 3769170]
7. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008; 88(2):581–609. [PubMed: 18391174]
8. Iliodromitis EK, Lazou A, Kremastinos DT. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. Vasc Health Risk Manag. 2007; 3(5):629–37. [PubMed: 18078014]
9. Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res. 2002; 55(3):438–55. [PubMed: 12160941]
10. Tong G, Aponte AM, Kohr MJ, Steenbergen C, Murphy E, Sun J. Postconditioning leads to an increase in protein S-nitrosylation. Am J Physiol Heart Circ Physiol. 2014; 306(6):H825–32. [PubMed: 24441547]
11. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). Journal of the American College of Cardiology. 2005; 45(11):1775–80. [PubMed: 15936605]
12. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. The New England journal of medicine. 2008; 359(5):473–81. [PubMed: 18669426]
13. Sun J, Morgan M, Shen RF, Steenbergen C, Murphy E. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circ Res. 2007; 101(11):1155–63. [PubMed: 17916778]
14. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal. 2011; 14(5):893–907. [PubMed: 20615076]
15. Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T, et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol. 2014;10.1016/j.yjmcc.2014.12.010
16. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009; 11(1):56–64. [PubMed: 19043407]
17. Cai C, Masumiya H, Weisleder N, Pan Z, Nishi M, Komazaki S, et al. MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem. 2009; 284(5):3314–22. [PubMed: 19029292]
18. Steenbergen C, Hill ML, Jennings RB. Volume regulation and plasma membrane injury in aerobic, anaerobic, and ischemic myocardium in vitro. Effects of osmotic cell swelling on plasma membrane integrity. Circ Res. 1985; 57(6):864–75. [PubMed: 4064260]
19. Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, Nishi M, et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem. 2009; 284(23):15894–902. [PubMed: 19380584]
20. Kohr MJ, Evangelista AM, Ferlito M, Steenbergen C, Murphy E. S-nitrosylation of TRIM72 at cysteine 144 is critical for protection against oxidation-induced degradation and cell death. J Mol Cell Cardiol. 2014; 69:67–74. [PubMed: 24487118]
21. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010; 121(23):2565–74. [PubMed: 20516375]

22. Zhang Y, Lv F, Jin L, Peng W, Song R, Ma J, et al. MG53 participates in ischaemic postconditioning through the RISK signalling pathway. *Cardiovasc Res.* 2011; 91(1):108–15. [PubMed: 21285295]
23. Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. *Nature.* 2013; 494(7437):375–9. [PubMed: 23354051]
24. Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. *Science translational medicine.* 2012; 4(139):139ra85.
25. Marshall KD, Edwards MA, Krenz M, Davis JW, Baines CP. Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes. *Am J Physiol Cell Physiol.* 2014; 306(7):C639–47. [PubMed: 24401845]
26. Li X, Xiao Y, Cui Y, Tan T, Narasimhulu CA, Hao H, et al. Cell membrane damage is involved in the impaired survival of bone marrow stem cells by oxidized low-density lipoprotein. *J Cell Mol Med.* 2014; 18(12):2445–53. [PubMed: 25256620]